Ipca Laboratories Ltd

IPCALAB

Company Profile

  • Business description

    Ipca Laboratories Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company is an integrated pharmaceutical company manufacturing and marketing over 350 formulations and various API's covering various therapeutic segments. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), and Losartan. The company has only one reportable primary business segment, pharmaceuticals. Geographically, the maximum revenue is derived from outside India, mainly from Europe, Africa, the Americas, Asia, etc.

  • Contact

    125, Kandivli Industrial Estate
    Kandivli (West)
    MumbaiMH400067
    IND

    T: +91 2262105000

    https://www.ipca.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 March 2027

    Employees

    23,467

Stocks News & Analysis

stocks

ASX biotech expands diagnostics portfolio after FDA approval

FDA nod adds another growth driver for ASX share.
stocks

Is it time to bail on Australian stocks?

Is your home bias costing your portfolio better returns?
stocks

ASX share undervalued despite margin woes

Short term margin pressure yet shares remain undervalued on improved outlook.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,874.5025.200.28%
CAC 408,140.5950.310.62%
DAX 4025,537.75135.470.53%
Dow JONES (US)51,567.15525.96-1.01%
FTSE 10010,688.4730.340.28%
HKSE24,713.7846.540.19%
NASDAQ25,970.2811.29-0.04%
Nikkei 22563,923.00438.900.69%
NZX 50 Index13,622.72138.501.03%
S&P 5007,554.1831.55-0.42%
S&P/ASX 2008,696.5024.000.28%
SSE Composite Index3,891.6027.320.71%

Market Movers